ID   ZR-75-B
AC   CVCL_5614
SY   ZR75-B; ZR-75B; ZR-75b; ZR75B
DR   CLO; CLO_0009924
DR   EFO; EFO_0001264
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   cancercelllines; CVCL_5614
DR   Cosmic; 1136345
DR   Cosmic; 1176641
DR   DepMap; ACH-002331
DR   GEO; GSM1053730
DR   GEO; GSM1172910
DR   GEO; GSM1173006
DR   GEO; GSM1215271
DR   LINCS_HMS; 51096
DR   LINCS_LDP; LCL-2077
DR   PharmacoDB; ZR75B_1691_2019
DR   Wikidata; Q54996122
RX   PubMed=6178756;
RX   PubMed=8562478;
RX   PubMed=9815641;
RX   PubMed=17157791;
RX   PubMed=18516279;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=25960936;
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 30.5 hours (PubMed=8562478; PubMed=9815641); 44.80 hours (GrayJW panel).
CC   HLA typing: B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01 (PubMed=25960936).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: ZRB75; Note=Occasionally.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=6178756; DOI=10.1172/JCI110624;
RA   Jolivet J., Schilsky R.L., Bailey B.D., Drake J.C., Chabner B.A.;
RT   "Synthesis, retention, and biological activity of methotrexate
RT   polyglutamates in cultured human breast cancer cells.";
RL   J. Clin. Invest. 70:351-360(1982).
//
RX   PubMed=8562478;
RA   Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T.M.,
RA   Gudas J.M., Bates S.E.;
RT   "Normal p53 status and function despite the development of drug
RT   resistance in human breast cancer cells.";
RL   Cell Growth Differ. 6:1395-1403(1995).
//
RX   PubMed=9815641;
RA   Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.;
RT   "Altered gene expression in drug-resistant human breast cancer
RT   cells.";
RL   Clin. Cancer Res. 3:2405-2414(1997).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//